Table 3.
Day Post Vaccination a | Study Arm b | Neutralization Assay c | ELISA antigen d | High Neutralization e | Low Neutralization | p value f |
---|---|---|---|---|---|---|
98 | rMVA-HIV(5) | VACV | p24 | 6/16 (37.5%) | 0/14 (0%) | 0.019 |
MVA | p24 | 3/15 (20.0%) | 3/15 (20.0%) | 1.000 | ||
VACV | gp120 | 14/16 (87.5%) | 6/14 (42.9%) | 0.019 | ||
MVA | gp120 | 10/15 (66.7%) | 10/15 (66.7%) | 1.000 | ||
154 | rMVA-HIV(5) | VACV | gp120 | 13/15 (86.7%) | 7/14 (50.0%) | 0.050 |
MVA | gp120 | 12/15 (80.0%) | 8/14 (57.1%) | 0.245 | ||
210 | rMVA-HIV(2)/rFPV-HIV(3) | VACV | p24 | 7/8 (87.5%) | 10/17 (58.8%) | 0.205 |
MVA | p24 | 9/10 (90.0%) | 9/16 (56.3%) | 0.099 | ||
rMVA-HIV(5) | VACV | gp120 | 13/14 (92.9%) | 5/14 (35.7%) | 0.004 | |
MVA | gp120 | 10/14 (71.4%) | 8/14 (57.1%) | 0.695 |
Enrollment is concurrent with the first vaccination; only time points with at least one comparison with p < 0.100 are shown
rMVA-HIV(5): 109 pfu/2 mL of rMVA for 5 vaccinations; rMVA-HIV(2)/rFPV-HIV(3): 109 pfu/2 mL of rMVA for 2 vaccinations followed by 109 pfu/2 mL of rFPV for 3 vaccinations
Neutralizing antibodies (NAb) assayed against either VACV-luciferase or MVA-luciferase
Binding antibodies measured against Gag (p24) or Env (gp120)
High neutralization: responder and ≥ median Nab titres for responders from the group; low neutralization: non-responders or < median titres for responders from the group
p value determined by two-tailed Fisher’s exact test comparing high neutralization vs low neutralization